BCRX BioCryst Pharmaceuticals
- 4.195
- +0.035+0.84%
BioCryst Pharmaceuticals News
With 80% Ownership, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Boasts of Strong Institutional Backing
BioCryst to Report First Quarter 2024 Financial Results on May 6
RESEARCH TRIANGLE PARK, N.C., April 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2024 financial results on Monday, May 6,
FYBR, BCRX and SABR Are Among After Hour Movers
Express News | BioCryst Pharmaceuticals Announced That The Brazilian Health Regulatory Agency Has Granted Approval For Oral, Once-daily ORLADEYO (Berotralstat) For The Prophylaxis Of Hereditary Angioedema (Hae) Attacks In Adults And Pediatric Patients 12 Years
Express News | BioCryst Announces Approval of Orladeyo® (Berotralstat) by the Brazilian Health Regulatory Agency
Express News | Needham Reiterates Buy on BioCryst Pharma, Maintains $12 Price Target
BioCryst Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/10/2024 147.42% Needham → $12 Reiterates Buy → Buy 01/08/2024 147.42% Needham → $12 Reiterates Buy → Bu
Why Investors Shouldn't Be Surprised By BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Low P/S
With a price-to-sales (or "P/S") ratio of 2.9x BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) may be sending very bullish signals at the moment, given that almost half of all the Biotechs companies in t
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., March 25, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the H.C. Wainwright 2nd Annual Autoimmune &
13 Best Biotech Stocks To Buy Under $20
Institutional Owners May Take Dramatic Actions as BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Recent 5.0% Drop Adds to One-year Losses
Key Insights Given the large stake in the stock by institutions, BioCryst Pharmaceuticals' stock price might be vulnerable to their trading decisions A total of 13 investors have a majority stake in
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., March 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the compensation committee of BioCryst's board of directors granted three newly-hired
New Regulation Risk for BioCryst Pharmaceuticals – What's the Latest?
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2023 Earnings Call Transcript
BioCryst Pharmaceuticals Files for a Mixed Securities Shelf
BioCryst Pharmaceuticals Full Year 2023 Earnings: EPS Misses Expectations
Q4 2023 BioCryst Pharmaceuticals Inc Earnings Call
What's Going On With BioCryst Stock After Earnings?
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares are flat Monday after the company reported its fourth-quarter financial results before the opening bell.The Details:BioCryst reported quarterly loss
10 Health Care Stocks With Whale Alerts In Today's Session
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth.
Earnings Call Summary | BioCryst Pharmaceuticals(BCRX.US) Q4 2023 Earnings Conference
The following is a summary of the BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2023 Earnings Call Transcript:Financial Performance:BioCryst Pharmaceuticals reported a total revenue of $326 million in 2023
Analysis
Price Target
No Data
